SG StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceuticals & Medical Research

NaN

0.000-0.97%

Number of Gainers:1

Number of Losers:2

Number of Flat:3

PE:- -

High:NaN

Open:NaN

Low:NaN

Close:NaN

Volume:7.46M

Turnover:7.24M

Market Cap:6.89B

Float Cap:4.02B

Loading ...

Singapore Shares Close Marginally Higher Despite Regional Losses; OUE REIT Climbs 4%

iX Biopharma Receives In-Principle Approval for Listing, Quotation of New Shares

MT Newswires Live

IX Biopharma Secures SGX Approval for S$6 Million Share Placement

IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds No Less Than S$6,000,000 - Receipt of Lqn

THOMSON REUTERS

IX Biopharma Ltd. Request for Lifting of Trading Halt - Sponsor's Statement

THOMSON REUTERS

BRIEF-IX Biopharma To Raise At Least S$6 MLN Via Placement At S$0.198 Per Share

IX Biopharma - to Raise at Least S$6 Mln via Placement at S$0.198 per Share

THOMSON REUTERS

IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds of No Less Than S$6,000,000 - Entry Into Placement Agrt

THOMSON REUTERS

IX Biopharma Ltd. U.S. Government Awards IX Biopharma US$41 Million Contract to Fund Development of Wafermine

THOMSON REUTERS

3 Singapore Dividend Stocks to Watch During CNY

The Smart Investor

IX Biopharma Ltd. Request for Trading Halt

THOMSON REUTERS

Controlling Shareholder Ups Stake in Tianjin Pharmaceutical Da Ren Tang; Shares Up 3%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK6506/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"BK6506","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","market":"SI","secType":"PLATE","nameCN":"Pharmaceuticals & Medical Research","latestPrice":3.0200564e-8,"timestamp":1771912989033,"preClose":3.049655e-8,"halted":0,"volume":7457100,"delay":0,"changeRate":-0.009706,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"02-24 14:04:06 SGT","open":3.048026e-8,"high":3.0631075e-8,"low":2.991697e-8,"amount":7241005,"amplitude":0.023416,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771924560000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771893000000,1771905600000],[1771909200000,1771924560000]],"pbRate":1.64608,"peRate":10.549281,"turnoverRate":0.006245,"increases":1,"decrements":2,"flats":4,"marketCap":6890307000,"floatMarketCap":4022361395.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK6506\",,,,,undefined,":{"symbol":"BK6506","high":3.0631075e-8,"amplitude":0.023416,"preClose":3.049655e-8,"low":2.991697e-8,"pbRate":"1.64608","latestPrice":3.0200564e-8,"volume":7457100,"delay":0,"open":3.048026e-8,"prevYearClose":1.4808467e-7,"prevWeekClose":0,"prevMonthClose":0,"prevQuarterClose":0,"fiveDayClose":0,"twentyDayClose":0,"sixtyDayClose":0,"secType":"PLATE","market":"SI","turnoverRate":0.006245,"peRate":10.549281,"marketCap":6890307000,"floatMarketCap":4022361395.75,"timestamp":1771912989033,"nameCN":"Pharmaceuticals & Medical Research"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK6506\",,,,undefined,":{"bkCode":"BK6506","up":1,"down":2,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK6506\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612263541","title":"Singapore Shares Close Marginally Higher Despite Regional Losses; OUE REIT Climbs 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612263541","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612263541?lang=en_us&edition=fundamental","pubTime":"2026-02-20 17:50","pubTimestamp":1771581000,"startTime":"0","endTime":"0","summary":"Singapore shares closed the week higher, with a modest uptick building on yesterday's powerful 1.3% surge, which saw the index crossing the 5,000 mark on Thursday.The Straits Times Index , a key benchmark for the Singapore Exchange, ranged between 4,993.43 and 5,024.57 throughout the day. It ended the session at 5,017.60, up 16.04 points or 0.3% compared to Thursday's close.On the corporate front, shares of OUE REIT  were up over 4% at the close after the REIT said that its subsidiary, OUB Centre, which holds an 81.54% stake in One Raffles Place, is conducting an exercise with United Overseas Bank  to assess market interest in the property.Nera Telecommunications  shares closed over 4% higher as it secured a three-year contract worth around SG$2.4 million from an institutional asset manager.Meanwhile, shares of iX Biopharma  were up over 2% at the close as it received in-principle approval from the Singapore Exchange Securities Trading for the listing and quotation of up to 75.8 millio","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","BK6072","N01.SI","BK6506","BK6005","42C.SI","STI.SI","TS0U.SI","BK6515","BK6512"],"gpt_icon":0},{"id":"2612847255","title":"iX Biopharma Receives In-Principle Approval for Listing, Quotation of New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612847255","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612847255?lang=en_us&edition=fundamental","pubTime":"2026-02-20 11:41","pubTimestamp":1771558905,"startTime":"0","endTime":"0","summary":"iX Biopharma  received an in-principle approval from the Singapore Exchange Securities Trading for the listing and quotation of up to 75.8 million shares to raise around SG$6 million, according to a Thursday filing with the Singapore Exchange.Shares of the specialty pharmaceutical and nutraceutical company were up over 2% in Friday trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6506","SG9999004360.SGD","LU2242646821.SGD","LU1920062954.HKD","LU0441851309.USD","SG9999014484.SGD","LU0877626530.USD","SGXZ27511609.SGD","LU1119993845.HKD","SG9999001846.SGD","LU2401740654.USD","SG9999016042.SGD","LU1839390173.USD","SG9999013460.SGD","LU2242646235.USD","SG9999000343.SGD","SGXZ58947870.SGD","LU2242652126.USD","LU1920063259.USD","LU0326948709.USD","LU0192582467.USD","42C.SI","BK6523","LU0898667661.SGD","SG9999013486.USD","BK6516","LU0532188223.SGD","LU0205439572.USD","LU0188438112.USD","BK6033","BK6079","SG9999013478.USD","SG9999014492.USD","IE00BKZH1Z71.USD","SG9999006266.SGD","SG9999001135.SGD","LU0831103253.SGD","SG9999003826.SGD"],"gpt_icon":0},{"id":"2612806409","title":"IX Biopharma Secures SGX Approval for S$6 Million Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2612806409","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612806409?lang=en_us&edition=fundamental","pubTime":"2026-02-19 18:46","pubTimestamp":1771497992,"startTime":"0","endTime":"0","summary":"IX Biopharma Ltd. said it has received in-principle approval from SGX-ST for the listing and quotation of up to 75.8 million new shares to be issued under its proposed placement, which is intended to raise gross proceeds of at least S$6 million. The company noted the placement remains subject to the fulfilment of conditions under the placement agreement and compliance with SGX-ST listing requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited   on February 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL9jJHrj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014484.SGD","42C.SI","LU1920063259.USD","BK6033","SG9999001846.SGD","SGXZ27511609.SGD","LU0192582467.USD","LU0188438112.USD","BK6079","IE00BKZH1Z71.USD","LU1920062954.HKD","LU1839390173.USD","SG9999006266.SGD","BK6523","LU0831103253.SGD","SG9999001135.SGD","LU2242652126.USD","LU2242646235.USD","SG9999013460.SGD","LU0326948709.USD","LU2401740654.USD","BK6506","SG9999013478.USD","SG9999004360.SGD","SGXZ58947870.SGD","SG9999000343.SGD","LU0441851309.USD","LU0898667661.SGD","LU1119993845.HKD","LU0205439572.USD","LU2242646821.SGD","SG9999016042.SGD","BK6516","SG9999003826.SGD","SG9999013486.USD","LU0877626530.USD","SG9999014492.USD","LU0532188223.SGD"],"gpt_icon":0},{"id":"2612409872","title":"IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds No Less Than S$6,000,000 - Receipt of Lqn","url":"https://stock-news.laohu8.com/highlight/detail?id=2612409872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612409872?lang=en_us&edition=fundamental","pubTime":"2026-02-19 18:46","pubTimestamp":1771497984,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUE34JYLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["42C.SI","BK6506","BK6079"],"gpt_icon":0},{"id":"2611875581","title":"IX Biopharma Ltd. Request for Lifting of Trading Halt - Sponsor's Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2611875581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611875581?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:18","pubTimestamp":1770963538,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUE5DKTZ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6079","BK6506","42C.SI"],"gpt_icon":0},{"id":"2610937978","title":"BRIEF-IX Biopharma To Raise At Least S$6 MLN Via Placement At S$0.198 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937978","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610937978?lang=en_us&edition=fundamental","pubTime":"2026-02-12 23:42","pubTimestamp":1770910969,"startTime":"0","endTime":"0","summary":"BRIEF-IX Biopharma To Raise At Least S$6 MLN Via Placement At S$0.198 Per ShareFeb 12 (Reuters) - IX Biopharma Ltd IXBI.SI:TO RAISE AT LEAST S$6 MILLION VIA PLACEMENT AT S$0.198 PER SHAREFurther company coverage: IXBI.SI ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6079","BK6506","42C.SI"],"gpt_icon":0},{"id":"2610942326","title":"IX Biopharma - to Raise at Least S$6 Mln via Placement at S$0.198 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2610942326","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610942326?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:53","pubTimestamp":1770893607,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","BK6079","42C.SI"],"gpt_icon":0},{"id":"2610942312","title":"IX Biopharma Ltd. Proposed Placement to Raise Gross Proceeds of No Less Than S$6,000,000 - Entry Into Placement Agrt","url":"https://stock-news.laohu8.com/highlight/detail?id=2610942312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610942312?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:52","pubTimestamp":1770893567,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUE97XJWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6079","42C.SI","BK6506"],"gpt_icon":0},{"id":"2610012944","title":"IX Biopharma Ltd. U.S. Government Awards IX Biopharma US$41 Million Contract to Fund Development of Wafermine","url":"https://stock-news.laohu8.com/highlight/detail?id=2610012944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610012944?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:45","pubTimestamp":1770893153,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUE8HZYWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK6506","BK6079","42C.SI"],"gpt_icon":0},{"id":"2610299476","title":"3 Singapore Dividend Stocks to Watch During CNY","url":"https://stock-news.laohu8.com/highlight/detail?id=2610299476","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610299476?lang=en_us&edition=fundamental","pubTime":"2026-02-12 11:30","pubTimestamp":1770867000,"startTime":"0","endTime":"0","summary":"Discover three Singapore dividend stocks hitting their stride this Chinese New Year.","market":"sg","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/02/Vicom-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/02/Vicom-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/3-singapore-dividend-stocks-to-watch-during-cny/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/3-singapore-dividend-stocks-to-watch-during-cny/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["SG9999013486.USD","SG9999014492.USD","LU0532188223.SGD","BK6506","LU1839390173.USD","BK6054","SG9999006266.SGD","SG9999000343.SGD","LU2242646235.USD","BK6029","IE00BKZH1Z71.USD","LU1920062954.HKD","ODBU.SI","U13.SI","SG9999013478.USD","SG9999016042.SGD","BK6512","IE0031814969.USD","LU0188438112.USD","BK6011","BK6520","LU0898667661.SGD","BK6523","LU0205439572.USD","SG9999003826.SGD","BK6516","LU2242652126.USD","SGXZ58947870.SGD","SG9999013460.SGD","LU0441851309.USD","SG9999004360.SGD","SG9999014484.SGD","BK6521","BK6033","BK6137","SG9999001846.SGD","LU1119993845.HKD","LU2242646821.SGD","LU2401740654.USD","SG9999001135.SGD","LU0192582467.USD","LU0877626530.USD","BK6079","LU1920063259.USD","SGXZ27511609.SGD","LU0831103253.SGD","WJP.SI","LU0326948709.USD"],"gpt_icon":0},{"id":"2610602911","title":"IX Biopharma Ltd. Request for Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2610602911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610602911?lang=en_us&edition=fundamental","pubTime":"2026-02-11 12:31","pubTimestamp":1770784317,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUE3BQKS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["42C.SI","BK6079","BK6506"],"gpt_icon":0},{"id":"2609559180","title":"Controlling Shareholder Ups Stake in Tianjin Pharmaceutical Da Ren Tang; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609559180","media":"MT Newswires","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609559180?lang=en_us&edition=fundamental","pubTime":"2026-02-06 14:17","pubTimestamp":1770358637,"startTime":"0","endTime":"0","summary":"JinYao Global, a subsidiary of Tianjin Pharmaceutical Da Ren Tang's  controlling shareholder, Tianjin Pharmaceutical, acquired additional S-Shares in the company at $2.96 apiece for $242,953, according to a Thursday filing with the Singapore Exchange.Shares of the pharmaceutical company were up over 3% in Friday trading.JinYao acquired 82,200 S-shares, representing around 0.0107% of the company's issued share capital. Following the acquisition of the new shares, the controlling shareholder's stake has increased to 43.008%.Meanwhile, JinYao Global has proposed to increase the shareholding further within six months, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Controlling Shareholder Ups Stake in Tianjin Pharmaceutical Da Ren Tang; Shares Up 3%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["T14.SI","BK6079","BK6506"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}